Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00034866 · ClinicalTrials.gov registry record · Phase 2

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

A Phase 2 study of HIV Infections, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 2
Development phase
165
Enrollment target
20
Study locations

NCT00034866 is a Phase 2 study of HIV Infections that has completed, run by Boehringer Ingelheim. The registered enrollment target is 165 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00034866, a Phase 2 study of HIV Infections, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 2
Development phase
165 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to determine which of three different dose combinations of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is most effective and safe. Tipranavir is an investigational protease inhibitor which has been demonstrated to have in vitro activity against HIV-1.

Conditions Studied

HIV Infections

Interventions

  • DRUG Protease inhibitor tipranavir

Study Locations (20)

California

  • Orange County Center for Special Immunology - Fountain Valley
  • Living Hope Clinical Trials Inc. - Long Beach
  • AHF Research Center - Los Angeles
  • University of So. California / LA County USC Medical Center - Los Angeles
  • ID Care, Inc. - Los Angeles
  • Tower I.D. Medical Assoc., Inc. - Los Angeles
  • University of California, Los Angeles Medical Center - Los Angeles
  • University of California San Francisco Positive Health Program Research - San Francisco
  • Pacific Horizon Medial Group - San Francisco

Florida

  • (IDC) Research Institute - Altamonte Springs
  • Therafirst Medical Center - Fort Lauderdale
  • Jackson Medical Tower - Miami
  • Steinhart Medical Associates - South Miami
  • Hillsborough County Health Dept. - Tampa
  • Treasure Coast Infectious Disease Consultants - Vero Beach

District of Columbia

  • Georgetown University Medical Center - Washington D.C.
  • Dupont Circle Physicians Group - Washington D.C.

Georgia

  • AIDS Research Consortium of Atlanta - Atlanta
  • Atlanta VA Medical Center, Dept. of ID - Decatur

Arizona

  • Phoenix Body Positive - Phoenix

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2002-04
Est. Completion 2002-10
Phase Phase 2

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00034866

The ClinicalTrials.gov registry entry for NCT00034866 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Protease inhibitor tipranavir is the first listed.

NCT00034866 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00034866 about?

NCT00034866 is a clinical study titled "Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals". The purpose of this research study is to determine which of three different dose combinations of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is most effective and safe. Tipranavir is an investigational protease inhibitor which has been demonstrated to have in...

What is the current status of trial NCT00034866?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2002-04. Estimated completion is 2002-10.

What conditions does trial NCT00034866 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00034866?

The interventions under investigation include: Protease inhibitor tipranavir (DRUG).

Who is sponsoring clinical trial NCT00034866?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00034866 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.